๐ข Recruiting
Phase 1
๐ Investigational Drug / Biologic
NCT05609994
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
๐ Duke University Medical Center โ Durham, North Carolina
View Study & Checklist โ